Innovodigm’s Big Break: Rs 5.5 Crore Seed Funding to Reinvent Vaccine Delivery
Medtech startup Innovodigm has just secured a seed round of Rs 5.5 crore, marking a significant milestone in its mission to transform how vaccines are delivered. Here’s the full scoop on who backed them, what they’re building, and why it really matters.
Who Invested in Innovodigm?
- Indian Angel Network (IAN) took the lead, investing Rs 4.5 crore.
- PadUp Ventures chipped in the remaining Rs 1 crore.
This fresh capital is earmarked for:
- Optimizing processes – streamlining workflows and production methods.
- Scaling infrastructure – upgrading labs and manufacturing setups.
- Expanding the team – adding experts to support upcoming milestones.
The seed round puts Innovodigm in prime position as it gears up for third-party preclinical studies and clinical trials. According to their press release, this funding marks a pivotal moment in moving from prototype to real-world testing.
Meet the Founders: Jhimli Manna & Ayan Chatterjee
Founded in 2020 by Jhimli Manna and Ayan Chatterjee, Innovodigm is driven by a simple yet bold vision: safer, easier, and more accessible vaccine delivery. They are the brains behind the innovation—and pushing boundaries in biotech and immunization.
What Is a Microneedle Array Patch (MAP)?
Innovodigm’s core technology is its proprietary Microneedle Array Patch, or MAP. Here’s why it’s an absolute game-changer:
- Needle-Free: No injections involved – the patch is applied to the skin.
- Thermostable: Can withstand 40 °C for up to 120 days, eliminating the need for stringent cold storage.
- Low-Waste: No syringes or needles—greatly reduces medical waste.
- Perfect for Remote Areas: Ideal for places with unreliable electricity or limited medical infrastructure.
Why This Matters
- Cold Chain Breakdown: Traditional vaccines need constant refrigeration. One break in the chain can ruin an entire batch.
- Medical Waste Problems: Syringes and needles mean hazardous waste—this patch kills that issue.
- Accessibility Boost: Easier to ship, store, and administer—no cold rooms or trained medical professionals required.
Early Acclaim & Institutional Credibility
Innovodigm’s MAP tech is already turning heads among key institutions:
- Nano Electronics Showcase 2025: Their patch was named one of the Top 2 Technologies, hosted by India’s Ministry of Electronics and IT.
- Material Transfer Agreement (MTA): They’ve partnered with a major Indian vaccine manufacturer to hand over MAP for independent testing—a vital step before moving to trials.
These endorsements add credibility and push them one step closer to real-world application.
What’s Next? Preclinical Tests & Clinical Trials
🧪 Third-Party Preclinical Validation
- Innovodigm is preparing to share its MAP technology for independent testing with a partner vaccine company.
- The goal: confirm safety, potency, and topline efficacy in animal or lab models.
👥 Clinical Trials on the Horizon (2026)
- If preclinical results are strong, the team will launch Phase I trials in 2026.
- Phase I will confirm safety in humans.
- Future phases (II/III) will test effectiveness and dosage—potentially leading to eventual regulatory approval.
Why It’s a Big Deal: The Global Vaccine Challenge
Here’s what makes Innovodigm’s innovation so pivotal:
- No Cold Storage = Remote Reach: Perfect for rural areas, refugee camps, or disaster zones.
- Syringe-Free = Safer & Cleaner: Less needle-stick risk, lower disposal costs.
- Long Shelf-Life: Lasts 4 months at high temps—great for emergency stockpiles.
- Simple Self-Administered Delivery: Could one day let people apply patches themselves, without going to a clinic.
Team Expansion and Infrastructure Build-Out
The Rs 5.5 Crore injection into Innovodigm isn’t just a symbolic vote of confidence—it’s the fuel they need to grow:
- Refine Production: Improve and standardize how MAP patches are manufactured.
- Upgrade Infrastructure: Better labs, manufacturing equipment, and supply chain setup.
- Grow the Team: Recruit biotech experts, engineers, clinical trial specialists, and regulatory advisors.
This groundwork is essential before they step into the testing phase.
Outlook: Will Innovodigm Lead the Vaccine Revolution?
Here’s why Innovodigm stands out:
- Thermostability & Convenience: Being stable at high temps with no refrigeration needs is unmatched in emerging markets.
- Early Recognition: Winning accolades and securing an MTA shows both credibility and commercial intent.
- Backing from IAN: With Indian Angel Network’s support, they’ve gained more than just capital—they’ve gained mentorship and clout.
🗓️ Keep an eye on 2026—it could be a breakthrough year if clinical trials validate their vision.
Wrapping It Up: The Future of Vaccination?
Innovodigm’s Microneedle Array Patch has the potential to be a revolutionary leap forward. If their trials prove successful, we could see a future where:
- Vaccines are safer, easier, and waste-free.
- Rural and disaster-hit communities get reliable access.
- Vaccine campaigns require minimal infrastructure and training.
This Rs 5.5 Crore seed round isn’t just fund-raising—it’s opening the door to a new era in global health.
